We are pioneering two new capabilities for natural human antibodies
Precision binding to pre-selected epitopes
Agonists, Antagonists, Conformation-specific, Conditional binders
Multi-specific symmetrical IgG binding to more than one target on the same Fab
Novel Capabilities
Precision binding to preselected epitopes
By designing antibodies that bind to predefined epitopes — the parts of antigens recognized by antibodies — we can create drugs that achieve specific functional effects. These antibodies can thus agonize or antagonize the target by precisely “pressing the right button”, they block one function of the target while sparing, or even enhancing, another function and give us better control of the biological process.
This enables Biolojic’s antibodies to have better efficacy, broader therapeutic windows and better dosing regimens.
Example – Aulos: Selective effector cells agonist for IO (a Biolojic’s spinout)
This is illustrated by AU-007, the first-ever computationally designed antibody to enter human clinical trials. AU-007 was designed by Biolojic to precisely bind to pre-defined epitope on interleukin-2 (IL-2) to redirect IL-2 toward cells that express dimeric receptors (T effs, NKs, NKTs), and away from cells that express the trimeric receptor (T regs, vascular endothelium). Thus, AU-007 unlocks the full potential of IL-2 to fight cancer: it starves the cells that protect the tumor and nourishes that cells that kill the tumor.
Unlocking the Power of IL-2
Interleukin-2 is often described as a “double-edged sword” because of its ability both to suppress and activate the immune system. For cancer patients, increased levels of IL-2 correlate with improved survival.
A multibody is an antibody that can bind to two or more targets on each of its arms. It is a standard symmetrical IgG antibody, in which each arm of the antibody is multi-specific. This structure allows us to attack different targets with a single drug. A multibody can act like different antibodies at different times, depending on the conditions in the body. They are essentially programmable nanobots that can execute “and” or “or” functions inside the body.
Multibodies can bind to two or more targets on each of its arms, allowing us to attack different targets at different times with a single drug.
- Logic gates: e.g. if X agonize A, if Y antagonize B
- Exchanger: bring target X to tissue A
- Sensors/actuators: respond to changes in concentration of X
A multibody can bind more than one target with the same Fab
Standard symmetrical IgG antibodies with two multi-specific arms
- Computationally designed multi specific Abs
- Maintains a natural symmetrical IgG format reducing the risk of ADAs
- Makes it possible to attack multiple targets with a single drug
- Can be programed to bind different targets under different conditions
- Does not come at the expense of affinity or specificity
- Simplified CMC compared to Bi-specifics